Sven Wehrwein sold $377k of ATRC
director at AtriCure, Inc.. 10,000 shares at an average of $37.66, traded Nov 24, 2025, filed Nov 26, 2025.
Score components
- +15RoleDirector
- +16Trade size$377k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001205069-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | MOption exercise Common Stock | +5,033 | $19.95 | $100k | 39,407 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock | -5,033 | $37.32 | $188k | 34,374 | Nov 26, 2025 |
| Nov 25, 2025 | MOption exercise Common Stock | +4,967 | $19.95 | $99k | 39,341 | Nov 26, 2025 |
| Nov 25, 2025 | SOpen-market sale Common Stock | -4,967 | $38.00 | $189k | 34,374 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Non-qualified Stock Option (right to buy)derivative | -5,033 | $0.00 | $0 | 29,967 | Nov 26, 2025 |
| Nov 25, 2025 | MOption exercise Non-qualified Stock Option (right to buy)derivative | -4,967 | $0.00 | $0 | 25,000 | Nov 26, 2025 |
Related signals
Other insiders at AtriCure, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $271k 4,519 shares | -3% | |
| 42Moderate | AtriCure, Inc. | Regina E Groves director | $288k 5,313 shares | -13% | |
| 15Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $201k 3,657 shares | -2% | |
| 19Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $408k 7,763 shares | -5% | |
| 26Weak | ATRCsell AtriCure, Inc. | Vinayak Doraiswamy Chief Scientific Officer | $149k 5,000 shares | -5% | |
| 42Moderate | AtriCure, Inc. | Justin J Noznesky Chief Mktg & Strategy Officer | $193k 5,166 shares | -6% | |
| 45Moderate | AtriCure, Inc. | Maggie Yuen director | $107k 3,000 shares | -21% | |
| 25Weak | ATRCsell AtriCure, Inc. | Justin J Noznesky Chief Mktg & Strategy Officer | $109k 3,000 shares | -3% | |
| 17Weak | ATRCsell AtriCure, Inc. | Sven Wehrwein director | $185k 5,000 shares | -13% | |
| 32Weak | AtriCure, Inc. | Sven Wehrwein director | $180k 5,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.